ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males

Inclusion Criteria: * Undergone either a radical prostatectomy, transurethral resection of the prostate or other prostate surgery at least 12 months prior without radiation therapy * Demonstrate primary stress urinary incontinence * Male subjects at least 45 years of age * Willing and able to undergo surgical implantation of the ProACT devices * Willing and able to comply with the follow-up requirements * Willing and able to forego any other surgical urinary incontinence treatments while participating in the study * Willing and able to sign the informed consent * Positive 24 hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests) * Experiences at least 3 incontinence episodes per day during two baseline voiding diaries. * Negative Urine culture * No recurrent stricture at the anastamosis * No known urogenital malignancy other than previously treated prostate cancer * Physician determines subject to be suitable surgical candidate Exclusion Criteria: * Primarily Urge incontinence * Detrusor instability or over-activity * Residual volume greater that 100 ml or greater than 25% of the total bladder capacity after voiding. * Subject has/had or is suspected of having bladder cancer * History of recurrent bladder stones * Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia * Known hemophilia or a bleeding disorder * Abnormal PSA (Prostate Specific Antigen), according to sites laboratory standards, unless further investigation confirms no underlying prostate malignancy. * Known sever contrast solution allergy * Has a genitourinary mechanical prosthesis other than previous sling procedure (e.g., Artificial Urinary sphincter, implantable penile prosthesis) * Has a urethral stricture that prevents passage of an 18 F cystoscope or has had more than one urethrotomy * Undergone bulking procedure within 6 months of the baseline assessment * Subject is currently enrolled or plans to enroll in another device or drug clinical trial. * Subject is currently using an indwelling catheter or condom catheter for treatment of incontinence and is not willing to discontinue use at least 4 weeks prior to baseline assessment.